Showing results (111-120 of 163) with videos related to
Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2017
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE TrialJorge E Cortes, Carlo Gambacorti-Passerini, Michael W Deininger, et al.Blood|August 30, 2002
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemiasOliver G Ottmann, Brian J Druker, Charles L Sawyers, et al.Chemmedchem|March 31, 2016
Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic LiabilitiesAhmed M Ali, Rodolfo F Gómez-Biagi, David A Rosa, et al.Plos One|July 2, 2009
ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapyClara I Aceves-Luquero, Anupriya Agarwal, Juan L Callejas-Valera, et al.Blood|October 9, 2014
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoproteinAnupriya Agarwal, Ryan J Mackenzie, Arnaud Besson, et al.Blood|June 14, 2012
Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survivalKyung Hee Chang, Abel Sanchez-Aguilera, Shuhong Shen, et al.Blood|July 17, 2004
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CMLThomas O'Hare, Roy Pollock, Eric P Stoffregen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2013
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trialRuben A Mesa, Jason Gotlib, Vikas Gupta, et al.Blood|April 23, 2017
miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon responseJared A Wallace, Dominique A Kagele, Anna M Eiring, et al.Leukemia|July 24, 2015
β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemiaA M Eiring, J S Khorashad, D J Anderson, et al.Pageof 17